Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02014441 · ClinicalTrials.gov registry record · Phase 2
Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec
A Phase 2 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
NCT02014441 is a Phase 2 study that has completed, run by Amgen. The registered enrollment target is 61 participants.
The verdict
NCT02014441, a Phase 2 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
Study Summary
The primary objective was to estimate the proportion of participants with detectable talimogene laherparepvec deoxyribonucleic acid (DNA) in the blood and urine at any time after administration of talimogene laherparepvec within the first 3 cycles.
Interventions
- DRUG Talimogene laherparepvec
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2014-04-07 |
| Est. Completion | 2018-04-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02014441
The ClinicalTrials.gov registry entry for NCT02014441 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Talimogene laherparepvec is the first listed.
NCT02014441 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02014441 about?
NCT02014441 is a clinical study titled "Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec". The primary objective was to estimate the proportion of participants with detectable talimogene laherparepvec deoxyribonucleic acid (DNA) in the blood and urine at any time after administration of talimogene laherparepvec within the first 3 cycles.
What is the current status of trial NCT02014441?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2014-04-07. Estimated completion is 2018-04-19.
What interventions are being tested in trial NCT02014441?
The interventions under investigation include: Talimogene laherparepvec (DRUG).
Who is sponsoring clinical trial NCT02014441?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.